RDT

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

Retrieved on: 
화요일, 6월 27, 2023
DARPin, Radioactive decay, SNMMI, Therapy, Molecule, Neoplasm, Molecular imaging, RDT, Nuclear medicine, Kidney, DLL3, Molecular Partners, Society of Nuclear Medicine and Molecular Imaging, Fine chemical, Medical imaging, CONCORD

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has announced it will present on its Radio DARPin Therapy (RDT) Platform at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held from June 24-27 in Chicago, Illinois.

Key Points: 
  • Molecular Partners’ RDT platform represents a unique and innovative approach for the delivery of radioactive payloads to solid tumors.
  • Molecular Partners is developing a portfolio of RDTs, both proprietary as well as in collaboration with external partners.
  • The tumor-associated protein Delta-like ligand 3 (DLL3) is the first disclosed target of Molecular Partner’s proprietary RDT candidates.
  • Molecular Partners has also demonstrated that through DARPin engineering it can reduce the uptake of DARPin radio conjugates in the kidneys and therefore reduce kidney damage, a key limitation of protein-based radio therapies.

Mangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Retrieved on: 
수요일, 6월 21, 2023
Sildenafil, Telehealth, Pepsi, Half-life, Marketing, Biotechnology, Oxytocin, RDT, Tablet, Mango, Entrepreneurship, Erectile dysfunction, Health, ED, Coca-Cola, Tadalafil

The launch of the Company’s Sildenafil based Mango ED product is scheduled to be available for purchase online this summer.

Key Points: 
  • The launch of the Company’s Sildenafil based Mango ED product is scheduled to be available for purchase online this summer.
  • Like the Company’s currently marketed and sold Tadalafil based Mango ED product, which leverages the same active ingredient found in Cialis™, the new Sildenafil-based Mango will still be compounded with Oxytocin and L-Arginine in a tasty Mango-flavored rapid dissolve tablet (RDT) and individually packaged in a master pack of six tablets per package.
  • “The ED market has already proven to be big enough to accommodate multiple competing products.
  • That sense should be amplified further by additional new products that we intend to launch in the upcoming months.

Liqid Powers Army Research Laboratory with World’s Largest Composable Supercomputers

Retrieved on: 
목요일, 5월 18, 2023
Data Management, Technology, Other Technology, Software, Military, Artificial Intelligence, Government Technology, Other Defense, Defense, Contracts, Hardware, Graphics processing unit, United States Army Combat Capabilities Development Command, CDI, HPCMP, ARL, Combat, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, Jean, United States Department of Defense, Research, High Performance Computing Modernization Program, Aberdeen, RDT, ENIAC, CCDC, CISD, Computation, Aberdeen Proving Ground, United States Army Research Laboratory, HPC, Engineering, GPU

Liqid, the global leader in composable disaggregated infrastructure (CDI) solutions, proudly announces the successful delivery and acceptance of the largest composable supercomputers by the U.S. Department of Defense (DoD).

Key Points: 
  • Liqid, the global leader in composable disaggregated infrastructure (CDI) solutions, proudly announces the successful delivery and acceptance of the largest composable supercomputers by the U.S. Department of Defense (DoD).
  • Liqid served as the prime contractor for the $32 million contract, delivering two systems to the Army Research Laboratory DoD Supercomputing Resource Center (ARL DSRC).
  • These systems boast the largest composable GPU pools worldwide, with 360 NVIDIA A100 GPUs.
  • Located at Aberdeen Proving Ground, Maryland, it operates under the Combat Capabilities Development Command (CCDC), U.S. Army Research Laboratory, Computational and Information Sciences Directorate (CISD).

Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

Retrieved on: 
목요일, 5월 11, 2023
SEQUOIA, DARPin, Antigen, Society, AACR, Nephrotoxicity, ASH, Therapy, DME, CD70, CD3, TAA, Neoplasm, TAT, Diabetic retinopathy, NAMD, American Society of Clinical Oncology, LR, SITC, American Association for Cancer Research, Immunotherapy, RDT, Toxicity, Research, FAP, Cell, Stem cell, ASCO, Service provider, Society for Immunotherapy of Cancer, Radiation, DLL3, International Symposium on Symbolic and Algebraic Computation, Novartis, Patient, CD123, Molecular Partners, CD33, CD40, Kidney, Depreciation, Ranibizumab, R, Letter, CHF, Tumor microenvironment, Targeted alpha-particle therapy, Pharmaceutical industry, Vaccine, CONCORD, AML

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending March 31, 2023.

Key Points: 
  • 53 LR:
    Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending March 31, 2023.
  • “This quarter we made advances across our portfolio, including two clinical-stage oncology programs, MP0317 for solid tumors and MP0533 for AML.
  • We anticipate analyzing these data and working with potential partners to determine the best combinations and indications for the program.
  • The Company continues to evaluate potential business opportunities for abicipar outside of internal development at Molecular Partners.

Audere Receives $9.35M Grant for Its Flagship HealthPulse AI™ Technology

Retrieved on: 
화요일, 4월 18, 2023
COVID-19, Technology, Medical Devices, Medical Supplies, Infectious Diseases, Health Technology, Biotechnology, General Health, Health, Artificial Intelligence, Aurum, PATH, Health equity, Data collection, Global health, Infection, RDT, LMIC, Incidence, Traction, Case management, Bill, Bill & Melinda Gates Foundation, Disease, Malaria, Pharmaceutical industry, Medical device

Audere has received a $9.35M grant from the Bill & Melinda Gates Foundation , a historical funder of Audere’s project development, in addition to support from PATH , FIND , the Aurum Institute , and other global health partners.

Key Points: 
  • Audere has received a $9.35M grant from the Bill & Melinda Gates Foundation , a historical funder of Audere’s project development, in addition to support from PATH , FIND , the Aurum Institute , and other global health partners.
  • “The Foundation provided Audere’s initial catalytic funding to drive new innovation in global health.
  • Audere has succeeded in not only developing cutting-edge technology, but also in offering the product for the benefit of global health.
  • This new grant positions us to cost-effectively scale the technology - essentially turning any camera into a quality RDT surveillance tool - thereby maximizing impact.

Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR

Retrieved on: 
금요일, 4월 14, 2023
Tissue, AACR, Therapy, Senior, Doctor of Philosophy, RDT, Delta, Radiation, DLL3, Novartis, Molecular Partners, Engineering, Kidney, Neoplasm, Poster, Research, Safety, Pharmaceutical industry, DARPin, CONCORD

Molecular Partners’ proprietary Radio DARPin Therapy (RDT) platform represents a unique and innovative delivery system designed to deliver radioactive payloads to solid tumors without accumulating in other tissues.

Key Points: 
  • Molecular Partners’ proprietary Radio DARPin Therapy (RDT) platform represents a unique and innovative delivery system designed to deliver radioactive payloads to solid tumors without accumulating in other tissues.
  • Data within the presentation demonstrate that both the affinity and small size of DARPins can have an impact on tumor penetration.
  • Previously reported data supporting the RDT platform presented at TAT-12 can be found here , while the latest results will be shared via a poster at AACR 2023 on April 18.
  • The poster will be made available on the Molecular Partners website .

Audere Launches HealthPulse TestNow™ Digital Companion App for Self-Testers

Retrieved on: 
수요일, 4월 5, 2023
Software, General Health, Philanthropy, Apps, Applications, Technology, Infectious Diseases, Artificial Intelligence, Health Technology, Foundation, COVID-19, Other Technology, Other Philanthropy, Health, SAHPRA, Built-in self-test, Health equity, Diagnosis, Partnership, RDT, Health Products Regulatory Authority, Collection, Digital, COVID-19 testing, Pharmaceutical industry

Audere , a digital health nonprofit developing solutions to advance health equity, today announced HealthPulse TestNow™ , the first COVID-19 app deployed in South Africa that supports self-testers with the administration and interpretation of rapid diagnostic tests (RDT).

Key Points: 
  • Audere , a digital health nonprofit developing solutions to advance health equity, today announced HealthPulse TestNow™ , the first COVID-19 app deployed in South Africa that supports self-testers with the administration and interpretation of rapid diagnostic tests (RDT).
  • HealthPulse TestNow™ helps ensure the accurate use of RDTs through easy-to-follow instructions, process control timers, and guided result interpretation.
  • “We are proud to announce the first deployment of HealthPulse TestNow™ in South Africa.
  • Medical Diagnostech’s COV ID-19 Antigen Self T est 1, the first COVID-19 self-test manufactured in Africa to receive South African Health Products Regulatory Authority (SAHPRA) approval in 2023, will be the first test covered by Audere’s HealthPulse TestNow™ digital companion app.

U.S Federal Defense Budget for Uncrewed Systems and Robotics Report FY 2023: Analysis of Approximately 400 RDT&E and Procurement Programs Supporting Uncrewed Vehicles - ResearchAndMarkets.com

Retrieved on: 
목요일, 3월 30, 2023
Military, Defense, PB, U.S. Department of Defense Strategy for Operating in Cyberspace, Atmosphere, National security, NDAA, Omnibus spending bill, Research, RDT, Organization, DOD, Robotics, AUVSI, National Defense Authorization Act for Fiscal Year 2018, UXV Combatant, Department of Defence, Legislation, Risk management, Construction, Tableau

The "FY 2023 - U.S Federal Defense Budget for Uncrewed Systems and Robotics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FY 2023 - U.S Federal Defense Budget for Uncrewed Systems and Robotics" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an analysis of approximately 400 RDT&E and procurement programs supporting uncrewed vehicles in the U.S. DOD for Fiscal Year 2023.
  • Detailed information on specific programs developing and procuring uncrewed systems in the air, ground, and maritime surface/subsurface domains.
  • Federal Defense Spending Report for Uncrewed Systems includes:
    Military organizations worldwide are continuing to integrate uncrewed vehicles (UxV) into their operations at a growing rate.

Infoscitex Restructures to Support Continued Growth

Retrieved on: 
월요일, 3월 13, 2023
Government, Machine learning, RDT, Research, IST, Simulation, Air Force Research Laboratory, Organization, Investment, United States Army Combat Readiness Center, Sensor, 311th Human Systems Wing, DCS, Air Force Life Cycle Management Center, Intelligence, United States Department of Defense, Air Force Personnel Center, Directorate of Military Intelligence, Engineering, Atmosphere of Earth, Growth, DARPA, Human, AFRL, Air force, Airline, Management

DAYTON, Ohio, March 13, 2023 /PRNewswire/ -- Infoscitex (IST) recently completed an organizational transition as part of its ongoing growth strategy.

Key Points: 
  • DAYTON, Ohio, March 13, 2023 /PRNewswire/ -- Infoscitex (IST) recently completed an organizational transition as part of its ongoing growth strategy.
  • Mike has reorganized his team into three organizations, focusing expertise and resources in key areas to facilitate and support sustained growth.
  • Tom has provided the Air Force with Human Systems support for 40 years, most recently focused in Human Autonomy coordination and Man-Machine Teaming research.
  • His portfolio consists of sensors and Intelligence, Surveillance and Reconnaissance research as well as intelligence analysis and threat modeling support.

Directed Energy Weapons Market worth $12.9 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
금요일, 3월 3, 2023
Plasma, Missile, Electromagnetism, Capability, Homeland security, Airborne, Chemical laser, Laser surgery, OEM, Weapon, Atmosphere of Earth, Laser, USD, Support, Conventional weapon, Law enforcement, RDT, Mechanical, Chemical substance, Geography, Deputy Assistant Secretary of the Navy (Research, Development, Test & Evaluation), Investment, KSTAM, Growth, Light, Region, GPS, Defense, Arms industry, Explosive, Radar

Based on product, the directed energy weapon market has been segmented into lethal and non-lethal weapons.

Key Points: 
  • Based on product, the directed energy weapon market has been segmented into lethal and non-lethal weapons.
  • Directed energy weapons can select a discrete target to transfer a beam or a field of electromagnetic energy, laser, radiofrequency, acoustic energy, and atomic energy particles, which causes disruption or damage to the target.
  • Speed is the fundamental difference between directed energy weapons and conventional projectiles, as directed energy weapons operate at the speed of light rather than the subsonic or supersonic speeds of projectile weapons.
  • Based on the range, the directed energy weapon market has been subdivided into less than 1 km and more than 1 km.